Form 4: Xenon Pharmaceuticals Director Equity Update

Director Elizabeth A. Garofalo acquired common shares through RSU vesting and received new equity grants.

Summary

• Director Elizabeth A. Garofalo acquired 2,645 common shares upon the vesting of restricted share units (RSUs) on June 1, 2026.
• The reporting person was granted 10,507 share options with an exercise price of $53.46 on June 3, 2026.
• The reporting person was granted 1,593 additional RSUs on June 3, 2026.
• The new equity grants are scheduled to vest on June 1, 2027, or the day before the 2027 annual meeting of shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding director compensation, having no material impact on the company's financial position.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standard equity compensation structure for board members.

Negatives

• None identified.

Risks

• Market price volatility affecting the value of granted options and RSUs.

Future Outlook

The director's new equity grants are set to vest in full on June 1, 2027, or the day prior to the 2027 annual shareholder meeting.

Industry Context

StockSavvy.ai notes that this filing represents routine director compensation and equity alignment, which is standard practice for biotechnology companies to retain board expertise.

Comparison to Industry Standards

• The equity grant structure is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• Vesting schedules tied to annual shareholder meetings are common in the industry to ensure director retention through the annual cycle.

Stakeholder Impact

• Minimal impact on shareholders as these are standard equity-based compensation awards.

Next Steps

• Vesting of new equity grants on June 1, 2027.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Form 4, Insider Trading, Equity Compensation, Director Compensation